ERBB2 and breast carcinoma: Among breast carcinomas, the molecular subtypes of BM appeared to reflect the known prognostic differences observed in primary tumours based on visual assessment (Figure 3), with hormone receptor–positive tumours showing the most favourable outcomes, followed by HER2‐positive subtypes (with or without hormone receptor co‐expression), and triple‐negative tumours exhibiting the poorest outcomes.